Notably, the HSP90α level is upregulated in patients with IPF and shows a good correlation to the disease severity, which strongly suggests that HSP90α is a possible diagnostic biomarker, as well as a therapeutic target, of IPF. This evidence concerns the gene HSP90AA1 and idiopathic pulmonary fibrosis.